Exchange: NASDAQ·Updated 05:18 AM EDT
News
all
press releases
Tilray Brands, Inc. (TLRY) Dips More Than Broader Market: What You Should Know
In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $4.72, denoting a -2.48% move from the preceding trading day.
Zacks
More News
Cannabis Operator CGC Rises 15% in a Month: Time to Buy, Hold or Sell?
Canopy Growth's cannabis business is showing signs of a turnaround, with revenue growth, improving margins and a narrower EBITDA loss fueling its rally.
Zacks
Tilray Brands, Inc. (TLRY) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $4.48, denoting a -4.07% move from the preceding trading day.
Zacks
Should You Buy ACB Stock Amid Curaleaf's Hostile Takeover Attempt?
Aurora Cannabis faces a potential Curaleaf takeover at a 45% premium, but investors must weigh the offer against ACB's standalone prospects.
Zacks
Tilray Brands Expects to Hit a Major Milestone for the Current Fiscal Year: $1 Billion in Annual Revenue. Here's How it Plans to Get There
Key PointsTilray's revenue rose by 11% in the 2026 fiscal year...
Nasdaq News: Markets
Should You Buy, Hold or Sell GTBIF Stock Post Q2 Earnings Release?
Green Thumb tops Q2 earnings and sales estimates, but can regulatory catalysts, buybacks and expansion plans outweigh pricing pressure and fierce competition?
Zacks
Should You Buy, Hold or Sell SNDL Stock Post Q4 Earnings Release?
SNDL sinks after weak Q2 2026 earnings, but can cost cuts and U.S. expansion through Parallel offset ongoing cannabis and liquor headwinds?
Zacks
Tilray Brands (TLRY) Stock Is Trending: Here's What You Should Know
Tilray Brands shares jumped 2.23% after hours as quarterly revenue beat estimates, despite earnings per share missing expectations.read more...
Benzinga
Tilray Brands, Inc. (TLRY) Reports Q4 Loss, Beats Revenue Estimates
Tilray Brands (TLRY) delivered earnings and revenue surprises of -2,050.00% and +9.14%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Is JAZZ Still the Best Cannabis Stock After Federal Rescheduling?
Jazz Pharmaceuticals pairs its FDA-approved CBD blockbuster with a diversified drug portfolio, offering medical cannabis exposure despite ongoing pipeline risks.
Zacks

Advertisement|Remove ads.